Shares of PTC Therapeutics PTCT were flat after the company reported Q1 results.
Quarterly Results
Earnings per share were down 1.10% over the past year to ($1.83), which missed the estimate of ($1.51).
Revenue of $117,942,000 rose by 72.79% from the same period last year, which beat the estimate of $98,800,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 04, 2021
Time: 04:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/m8bp48ft
Recent Stock Performance
52-week high: $70.82
Company's 52-week low was at $39.68
Price action over last quarter: down 32.38%
Company Description
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
